In the Palani study11, eighty-three ABL kinase mutations were detected in 65 CP-CML patients at the time of imatinib failure with 35% of patients (23 of 65) harboring P-loop mutations (including M244V), 18% (12 of 65) with T315I mutation and 46% (30 of 65) with other mutations (catalytic domain, imatinib binding site, activation loop and C-terminal). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.